FR2861078B1 - NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE - Google Patents

NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE

Info

Publication number
FR2861078B1
FR2861078B1 FR0312087A FR0312087A FR2861078B1 FR 2861078 B1 FR2861078 B1 FR 2861078B1 FR 0312087 A FR0312087 A FR 0312087A FR 0312087 A FR0312087 A FR 0312087A FR 2861078 B1 FR2861078 B1 FR 2861078B1
Authority
FR
France
Prior art keywords
igg3
news
useful
stimulate phagocytosis
phagocytosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0312087A
Other languages
English (en)
Other versions
FR2861078A1 (fr
Inventor
Romeuf Christophe De
Sylvie Jorieux
Dominique Bourel
Philippe Klein
Nicolas Bihoreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0312087A priority Critical patent/FR2861078B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to CA002542508A priority patent/CA2542508A1/fr
Priority to PCT/FR2004/002657 priority patent/WO2005037866A2/fr
Priority to US10/575,218 priority patent/US20070218052A1/en
Priority to EP04817229A priority patent/EP1675616A2/fr
Priority to JP2006534803A priority patent/JP2007533639A/ja
Priority to BRPI0415420-7A priority patent/BRPI0415420A/pt
Priority to AU2004281220A priority patent/AU2004281220A1/en
Publication of FR2861078A1 publication Critical patent/FR2861078A1/fr
Priority to IL174949A priority patent/IL174949A0/en
Application granted granted Critical
Publication of FR2861078B1 publication Critical patent/FR2861078B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FR0312087A 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE Expired - Fee Related FR2861078B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0312087A FR2861078B1 (fr) 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
PCT/FR2004/002657 WO2005037866A2 (fr) 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose
US10/575,218 US20070218052A1 (en) 2003-10-16 2004-10-18 Novel lgG3 Antibodies for Stimulating Phagocytosis
EP04817229A EP1675616A2 (fr) 2003-10-16 2004-10-18 Nouvelles igg3 utiles pour stimuler la phagocytose
CA002542508A CA2542508A1 (fr) 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose
JP2006534803A JP2007533639A (ja) 2003-10-16 2004-10-18 強い食作用活性を有するＹＢ２／０細胞株の抗ＲＨＥＳＵＳ−ＤＩｇＧ３
BRPI0415420-7A BRPI0415420A (pt) 2003-10-16 2004-10-18 igg3 úteis para estimular a fagocitose
AU2004281220A AU2004281220A1 (en) 2003-10-16 2004-10-18 IGG3 anti rhesus-D in the line YB2/0 having a high phagocytosis activity
IL174949A IL174949A0 (en) 2003-10-16 2006-04-11 ANTI RHESUS-D IgG3 IN A YB2/0 CELL LINE HAVING A STRONG PHAGOCYTOSIS ACTIVITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0312087A FR2861078B1 (fr) 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE

Publications (2)

Publication Number Publication Date
FR2861078A1 FR2861078A1 (fr) 2005-04-22
FR2861078B1 true FR2861078B1 (fr) 2007-09-21

Family

ID=34385205

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0312087A Expired - Fee Related FR2861078B1 (fr) 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE

Country Status (9)

Country Link
US (1) US20070218052A1 (fr)
EP (1) EP1675616A2 (fr)
JP (1) JP2007533639A (fr)
AU (1) AU2004281220A1 (fr)
BR (1) BRPI0415420A (fr)
CA (1) CA2542508A1 (fr)
FR (1) FR2861078B1 (fr)
IL (1) IL174949A0 (fr)
WO (1) WO2005037866A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496548A (en) * 1987-09-18 1996-03-05 National Blood Authority Human anti-RH(D) monoclonal antibodies, cell lines and methods of use of antibodies in immunoassays
DE69328135D1 (de) * 1992-06-26 2000-04-27 Aetsrn Menschliche monoklonale Antikörper gegen Rhesus D und Zellinien die diese produzieren
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions

Also Published As

Publication number Publication date
BRPI0415420A (pt) 2006-12-05
JP2007533639A (ja) 2007-11-22
IL174949A0 (en) 2006-08-20
AU2004281220A1 (en) 2005-04-28
WO2005037866A8 (fr) 2006-06-01
CA2542508A1 (fr) 2005-04-28
FR2861078A1 (fr) 2005-04-22
WO2005037866A3 (fr) 2005-07-21
US20070218052A1 (en) 2007-09-20
EP1675616A2 (fr) 2006-07-05
WO2005037866A2 (fr) 2005-04-28

Similar Documents

Publication Publication Date Title
IS3021B (is) Mótefni gegn M-CSF
EE200300509A (et) Antikehad VLA-1 vastu
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
NO20054681D0 (no) Farmasoytiske produkter
IS7806A (is) Ónæmisvaldandi samsetning
DE602004017700D1 (de) Transmukosen verabreichung
DK1545662T3 (da) Lægemiddelindgivelsessystem
FI20011478A0 (fi) Farmaseuttinen koostumus
DE60311307D1 (de) Shampoo-zusammensetzungen
MX266708B (es) Formulaciones de microparticulas de pantoprazol.
DE60318132D1 (de) Haarwaschmittel
AU2002364954A8 (en) Antibodies that immunospecifically bind to blys
NO20023942L (no) Tablettmater
NO20033042L (no) Cyklodekstrin-inneholdende farmasöytisk preparat
DK1587478T3 (da) Farmaceutisk sammensætning
IS7051A (is) Lyfjasamsetningar
DE60319547D1 (de) Haarwaschmittel
DE602004004736D1 (de) Haarwaschmittel
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
FI20022128A (fi) Farmaseuttinen koostumus
DK1474152T3 (da) Orodispergerbar farmaceutisk sammensætning omfattende ivabradin
DE60237557D1 (de) Geschwindigkeitsgesteuerte Exzentervorrichtung
FR2861078B1 (fr) NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
DE60335978D1 (de) Haarwaschmittel
ITPD20030151A1 (it) Riduttore di velocita'

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20140630